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Abstract
Nuclear receptor coactivator 1 (NCOA1) plays crucial roles in the regulation of gene 
expression mediated by a wide spectrum of steroid receptors such as androgen recep-
tor (AR), estrogen receptor α (ER α), and estrogen receptor β (ER β). Therefore, 
dysregulations of NCOA1 have been found in a variety of cancer types. However, the 
clinical relevance and the functional roles of NCOA1 in human esophageal squamous 
cell carcinoma (ESCC) are less known. We found in this study that elevated levels of 
NCOA1 protein and/or mRNA as well as amplification of the NCOA1 gene occur in 
human ESCC. Elevated levels of NCOA1 due to these dysregulations were not only 
associated with more aggressive clinic‐pathologic parameters but also poorer sur-
vival. Results from multiple cohorts of ESCC patients strongly suggest that the levels 
of NCOA1 could serve as an independent predictor of overall survival. In addition, 
silencing NCOA1 in ESCC cells remarkably decreased proliferation, migration, and 
invasion. These findings not only indicate that NCOA1 plays important roles in 
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1 |  INTRODUCTION
Signaling pathways involved in the sex steroid recep-
tors play important roles not only in cancers typically 
responsive to sex hormones (ie, breast and prostate 
cancers) but also those classically considered as non‐
hormone responsive such as lung, liver, kidney, skin, 
and gastrointestinal cancers.1-3 Functionally, sex ste-
roid receptors such as estrogen receptor (ER) and an-
drogen receptor (AR) serve as transcription factors by 
recruiting multiple coactivators.4,5 By collaborating 
with transcription factors, coactivators play crucial 
roles in chromatin remodeling and regulation of gene 
expression.6-12 Nuclear receptor coactivator 1 (NCOA1, 
also known as SRC‐1) is the founding member of the 
nuclear receptor coactivator family.2,13 In addition to 
serving as a coactivator of AR14,15 and ER,16,17 NCOA1 
is also involved in transcriptional regulation of genes 
by interacting with other transcriptional factors. It 
has been reported that dysregulation of NCOA1 is in-
volved in the initiation and progression of different 
cancers.18-21 NCOA1 overexpression is associated with 
lymph node metastasis and enhances cell proliferation 
in prostate cancer.14 The levels of NCOA1 also cor-
relate with malignancy, recurrence, and therapeutic re-
sistance.22-24 For example, elevated levels of NCOA1 
can enhance breast cancer cell proliferation25,26 and 
metastasis.16,27,28 By enhancing Wnt/β‐catenin signal-
ing, NCOA1 is capable of promoting hepatocellular 
carcinoma progression.2
Esophageal squamous cell carcinoma (ESCC) is the 
third most common malignancy of the digestive tract and 
the fifth leading cause of cancer‐related death world-
wide.29-36 The prognosis of ESCC remains to be poor with 
5‐year survival rate <20%.37-41 In this study, we found that 
NCOA1 is highly enriched in human ESCC, and the levels 
of NCOA1 are clinically important in ESCC progression 
and patient prognosis. Functional studies demonstrated 
that NCOA1 is capable of promoting ESCC cell growth 
and progression. Multiple lines of evidence derived from 
the current study underscore the potential for NCOA1 to 
be developed as a biomarker of ESCC and a molecular 
target of treatment.
2 |  MATERIALS AND METHODS
2.1 | Population
Totally, 80 paraffin‐embedded tissue samples from human 
primary ESCC and their paired adjacent normal tissues 
were collected in the Affiliated Tumor Hospital of Shantou 
University Medical College from 2010 to 2011. All ESCC 
patients were clinically diagnosed and confirmed histologi-
cally. No subjects underwent adjuvant or chemotherapy or 
radiation treatment prior to surgery. The study protocol was 
reviewed and approved by the Ethics Committee of Shantou 
University Medical College.
2.2 | Tissue microarray array (TMA) and 
immunohistochemistry (IHC)
Paraffin blocks with tumor tissues were identified by he-
matoxylin and eosin (H&E), and areas with respective his-
topathological features were marked on the block. The 
cylindrical tumor cores were punched and transferred to the 
recipient block using a 2.0‐mm diameter precision punch. 
Blocks of the tissue microarray (TMA) were cut into 4‐μm 
sections and processed for IHC as described previously.42-45 
TMA slides were incubated with anti‐NCOA1 antibody 
(sc‐8995, Santa Cruz) at room temperature for 1 hour fol-
lowed by incubation with the HRP‐conjugated secondary an-
tibody at room temperature for 30 minutes. Immunostaining 
was visualized by 3, 3′‐diaminobenzidine (DAB), and the cell 
nuclei were counterstained by hematoxylin. Immunostaining 
intensities were semi‐quantitatively graded by the percentage 
of positive cells. Each staining was evaluated by two inde-
pendent investigators who were unaware of the clinical and 
pathological information. Receiver operating characteristic 
(ROC) curve analysis was performed to assess cutoff score 
for overexpression of NCOA1.
2.3 | Bioinformatics analysis
The ESCC dataset (GSE63941) from Gene Expression 
Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) was 
used to estimate the mRNA levels of NCOA1 in ESCC cell 
Foundation; Technion‐Israel Institute of 
Technology; Shantou University human ESCC but the levels of NCOA1 also could serve as a potential prognostic bio-
marker of ESCC and targeting NCOA1 could be an efficacious strategy in ESCC 
treatment.
K E Y W O R D S
coregulator, esophageal carcinoma, invasiveness, migration, proliferation, sex steroid receptor signaling, 
SRC‐1
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lines. A dataset (titled “Hu Esophagus 2 statistics”) from 
the Oncomine database (https://www.oncomine.org//) was 
used to analyze the copy numbers of NCOA1 in ESCC 
tissues. A TCGA dataset named Esophageal Carcinoma 
(TCGA, Provisional), which includes esophageal adeno-
carcinoma (EA) and ESCC patients, was obtained from the 
cBioPortal (https://www.cbioportal.org/). The expression 
profiles of ESCC specimens (n = 95) were extracted and 
used to access the NCOA1 expression.
2.4 | Cells and cell culture
The ESCC cell lines including KYSE510 (obtained from 
the tumor cell bank of the Chinese Academy of Medical 
Science), HKESC‐1, and HKESC‐2 (kindly provided by Dr 
SW Tsao, the University of Hong Kong) were cultured in 
RPMI‐1640 Medium (Invitrogen, Carlsbad, CA).32 TE‐1 and 
TE‐12 cells (kindly provided by Dr SW Tsao, the University 
of Hong Kong) were grown in Dulbecco’s modified Eagle’s 
medium (Invitrogen) supplemented with 10% fetal bovine 
serum (FBS; HyClone, Logan, UT).32 The immortalized es-
ophageal cell lines (NE2, kindly provided by Dr SW Tsao, 
the University of Hong Kong) were maintained in medium 
of 1:1 mixture of DK‐SFM: Epi‐Life serum‐free medium 
(Invitrogen).32 All cells were maintained in monolayer at 
37°C in humidified air with 5% CO2.
2.5 | Generation of stable cell lines
KYSE510 cells were transfected with plasmid expressing 
shRNA targeting NCOA1 (shNCOA1 #1 and shNCOA1 
#2) or shControl vector (shCtrl) using lipofectamine 
3000 (Life Technologies, Carlsbad, MD, USA) accord-
ing to the manufacturer’s instructions. Stable cells were 
selected by culturing the cells in the medial with puro-
mycin for 2 weeks. The sequences of shNCOA1 #1 and 
shNCOA1 #2 are CCTCAGGGCAGAGAACCATCT and 
CACGACGAAATAGCCATAC, respectively.
2.6 | Western blotting
Whole cell lysates were prepared by lysing the cells in lysis 
buffer, and cell lysates with equal amount of proteins were 
separated on 10% SDS‐PAGE and transferred to PVDF 
membranes. The membranes were then incubated with pri-
mary antibodies at 4°C overnight. The primary antibod-
ies used in this study were anti‐NCOA1 (sc‐8995; Santa 
Cruz, CA, USA) and anti‐Tubulin (sc‐9104; Santa Cruz). 
Membranes were then probed with secondary antibodies for 
1 hour at room temperature. Blotted proteins were visualized 
by incubating in SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific) followed by exposure to X‐ray 
film (Eastman Kodak, Rochester, NY, USA).
2.7 | Cell proliferation assay
Real‐time cell analysis (RTCA) was performed to esti-
mate cell proliferation using the xCELLigence DP de-
vice (ACEA Biosciences) as described in the supplier’s 
instructions. In brief, two thousand cells were seeded 
in E‐plates, and the plates were locked into the RTCA 
DP device supplied with humidified air with 5% CO2 
at 37°C. The proliferative ability was monitored by the 
xCELLigence RTCA Analyzer (Roche Applied Science, 
Mannheim, Germany).
2.8 | Quantitative real‐time PCR
Total RNA was extracted from cells using TRIzol 
(Invitrogen) according to the manufacturer’s instruction and 
2 μg RNA was reversely transcribed using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA, USA). The cDNA was used as template for 
quantitative real‐time PCR with the following primers for 
NCOA1: 5′‐GAATCCTTGGGACCTCTT‐3′ (forward) and 
5′‐TGGCTATTTCGTCGTGTT‐3′ (reverse) and for β‐actin 
5′‐GAACCCCAAGGCCAACCGCGAGA‐3′ (forward) and 
5′‐TGACCCCGTCACCGGAGTCCATC‐3′ (reverse).
2.9 | Cell migration and invasion assay
Cell migration and invasion assays were conducted 
using the xCELLigence RTCA Analyzer (Roche Applied 
Science, Mannheim, Germany). Briefly, 150 μL of 
RPMI‐1640 supplemented with 10% FBS was added to the 
lower chamber in the CIM‐16 plate (16‐well, 8‐μm pore 
filter) and 3 × 104 cells in 100 μL of serum‐free RPMI1640 
were added to the upper chamber coated with or without 
Matrigel (BD Biosciences, Bedford, MA, USA). Cell index 
values that represented relative changes in electrical im-
pedance on the underside of the 8‐μm pore membrane were 
taken at a 3‐hours interval.
2.10 | Gene set enrichment analysis
Microarray data (accession no. GSE23400) were obtained 
from the Gene Expression Omnibus of NCBI (https://
www.ncbi.nlm.nih.gov/geo/) and subjected to Gene set 
enrichment analysis (GSEA) using GSEA software (ver-
sion 2.0.13; https://www.broadinstitue.org/gsea/index.
jsp).42,44
2.11 | Statistical analysis
SPSS 13.0 (SPSS Inc, Chicago, IL) was used to analyze the 
data. The correlation between the expression of NCOA1 and 
clinic‐pathological features of ESCC patients was examined 
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by chi‐square test. Student’s (or paired) t test was conducted 
for comparisons between two groups. All data were ex-
pressed as mean ± SD. A P‐value <0.05 is considered statis-
tically significant.
3 |  RESULTS
3.1 | Overexpression of NCOA1 in human 
ESCC
Given the fact that dysregulation of NCOA1 was found in mul-
tiple types of cancers, we were interested in knowing if this 
coactivator plays any role in ESCC. To do so, we first exam-
ined both the mRNA levels and the copy numbers of NCOA1 
in human ESCC. Analysis of the Oncomine database46 found 
that the copy number of NCOA1 in human ESCC speci-
mens (n = 30) is higher than that in blood samples (n = 12; 
P < 0.001, Figure 1A) suggesting a potential gene amplifica-
tion of NCOA1 in ESCC. In line with this finding, we found that 
15 of 22 ESCC cell lines in a published dataset (GSE63941) 
with higher levels of NCOA1 mRNA than that of fibroblast 
from normal esophageal tissue (Figure 1B). Immunoblotting 
assays showed that compared to that in the NE2, an immortal-
ized esophageal epithelial cell line, all 5 examined ESCC cell 
lines showed elevated protein levels of NCOA1 (Figure 1C). 
Next, we conducted a tissue microarray (TMA) to compare 
the NCOA1 protein levels in ESCC specimens with their ad-
jacent non‐tumor tissues (ANT) from 80 ESCC patients. The 
immunohistochemical staining results showed that the NCOA1 
levels are significantly higher in the ESCC tissues than that of 
the paired ANT (P < 0.01, Figure 2). These results altogether 
suggest that higher NCOA1 is associated with human ESCC.
3.2 | The levels of NCOA1 in ESCC 
progression and patient overall survival
To determine the clinical importance of elevated levels of 
NCOA1 in human ESCC, we first compared NCOA1 ex-
pression with the other clinicopathological parameters in the 
abovementioned cohort of 80 ESCC patients and found that 
F I G U R E  1  NCOA1 is upregulated 
in human ESCC cells. A, Comparison 
of the gene copy numbers of NCOA1 in 
ESCC with that in the blood in Oncomine 
database. B, The mRNA levels of NCOA1 
in ESCC cell lines (filled bars) and normal 
esophageal cells (open bars) were obtained 
from the ESCC dataset GEO, GSE63941. C, 
The protein levels of NCOA1 in a panel of 
ESCC cell lines estimated by a Western blot 
with tubulin as an internal control
   | 5209Wang et al.
the NCOA1 level was not relevant to any clinical‐pathologi-
cal parameters except the tumor size (P = 0.030, Table 1). 
Analysis of the TCGA dataset did not reveal any correlation 
between the clinicopathological parameters and NCOA1 ex-
pression either (Table 2). Then, we validated a reasonable 
cutoff score for NCOA1 overexpression by performing a re-
ceiver operating characteristic (ROC) curve analysis (Figure 
3A). Minimum threshold score for overexpression was set at 
6 (Immunochemistry score), which was closest to the point 
with both maximum sensitivity and specificity. The cases 
with scores ≤6 were defined as a low expression of NCOA1, 
whereas those with scores >6 were defined as overexpression 
of NCOA1. Based on these criteria, Kaplan‐Meier analysis 
found that ESCC patients with overexpression of NCOA1 
F I G U R E  2  NCOA1 is overexpressed in human ESCC tissues. Representative immunohistochemistry images of NCOA1 (brown) in ESCC 
sections (n = 80) and their paired adjacent non‐tumor tissues (ANT). Nuclei were counterstained with hematoxylin (blue; Left panels). The 
immunohistochemistry score of NCOA1 in ESCC (filled bar) and their paired adjacent non‐tumor tissues (ANT; open bar) tissues were plotted 
(right panel). **P < 0.01 by Student's t test
Variables No. of patients NCOA1 level P‐value
Low, no. (%) High, no. (%)
Total samples 80 38 (47.5) 42 (52.5)
Age (years)
≤60 41 19 (46.3) 22 (53.7) 0.832
>60 39 19 (48.7) 20 (51.3)
Gender
Female 19 10 (52.6) 9 (47.4) 0.796
Male 61 28 (45.9) 33 (54.1)
Tumor depth
T1/T2 13 6 (46.2) 7 (53.8) 0.519
T3/T4 67 32 (47.8) 35 (52.2)
Tumor size
<5 49 21 (42.9) 28 (57.1) 0.030
≥5 31 6 (19.4) 25 (80.6)
Stage
I/II 22 11 (50.0) 11 (50.0) 0.203
III/IV 58 27 (46.6) 31 (53.4)
pN status
N1‐N3 45 20 (44.4) 25 (55.6) 0.535
N0 35 18 (51.4) 17 (48.6)
High in this analysis is based on a NCOA1 level >6; the remaining individuals were classified as low.
T A B L E  1  The clinicopathological 
characteristics related to NCOA1 expression 
in specimens of 80 ESCC patients
5210 |   Wang et al.
Variables No. of patients NCOA1 level P‐value
Low, no. (%) High, no. (%)
Total samples 95 29 (30.5) 66 (69.5)
Age (years)
≤60 70 20 (28.6) 50 (71.4) 0.644
>60 25 9 (36.0) 16 (64.0)
Gender
Female 14 1 (7.1) 13 (92.9) 0.057
Male 81 28 (34.6) 53 (65.4)
Distant metastasis
M0 51 28 (54.9) 23 (45.1) 1.000
M1 44 1 (2.3) 43 (97.7)
Tumor depth
T1/T2 41 10 (24.4) 31 (75.6) 0.371
T3/T4 54 19 (35.2) 35 (64.8)
Stage
I/II 65 17 (26.2) 48 (73.8) 0.236
III/IV 30 12 (40.0) 18 (60.0)
Differentiation
Poor 26 5 (19.2) 21 (80.8) 0.211
Moderate‐Well 69 24 (34.8) 45 (65.2)
Alcohol use
Yes 69 20 (29.0) 49 (71.0) 1.000
No 26 9 (34.6) 17 (65.4)
pN status
N1‐N3 40 14 (35) 26 (65) 0.368
N0 55 15 (27.3) 40 (72.7)
High in this analysis is based on a NCOA1 level >1463.4; the remaining individuals were classified as low.
T A B L E  2  The clinicopathological 
characteristics related to NCOA1 expression 
in 95 ESCC primary specimens from TCGA 
dataset
F I G U R E  3  NCOA1 overexpression and poor clinical outcomes of ESCC. A, ROC curve analysis was performed to identify the optimal 
cutoff value for the overexpression of NCOA1. The sensitivity and specificity of each cutoff point for NCOA1 were calculated, and the results were 
plotted as a ROC curve. IHC stained samples were grouped into high NCOA1 expression (n = 42) and low NCOA1 expression (n = 38) by ROC 
analysis. B, Kaplan‐Meier curves showed the overall survival of 80 ESCC patients with high and low protein levels of NCOA1. C, The relationship 
between overall survival and mRNA levels of NCOA1 in a cohort of 95 ESCC patients
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have poor overall survival; the median survival time for 
ESCC patients with high NCOA1 was 16.0 months com-
pared to 41.0 months for those with low NCOA1 expression 
(P = 0.017, log‐rank test, Figure 3B). We further validated our 
findings in an ESCC‐related dataset (n = 95) from TCGA. To 
validate a reasonable cutoff score for NCOA1 overexpression, 
a receiver operating characteristic (ROC) curve analysis was 
performed, and the cutoff score for NCOA1 overexpression 
was set at 1463.4 (mRNA expression value), which was clos-
est to the point with both maximum sensitivity and specificity. 
The cases with scores ≤1463.4 were defined as a low NCOA1, 
whereas those with scores >1463.4 were defined as overex-
pression of NCOA1 (Figure S1). Figure 3C showed that ESCC 
patients with high NCOA1 expression are closely associated 
with poorer overall survival (P = 0.014, log‐rank test). In ad-
dition, Multivariate Cox regression analysis of the 80 patient 
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P‐value HR (95% CI) P‐value
Age
≤60 vs >60 1.793 (0.892‐3.606) 0.101 2.260 (0.982‐5.202) 0.055
Gender
Male vs Female 1.106 (0.496‐2.463) 0.806 1.715 (0.716‐4.107) 0.226
pTNM stage
III‐IV vs I‐II 2.391 (1.119‐5.106) 0.024 2.952 (0.788‐11.052) 0.108
NCOA1 expression
High vs Low 2.27 (1.128‐4.570) 0.022 2.386 (1.049‐5.426) 0.038
pN status
N1‐N3 vs N0 2.164 (1.000‐4.682) 0.050 1.300 (0.502‐3.371) 0.589
Tumor depth
T1/T2 vs T3/T4 2.572 (0.783‐8.447) 0.119 1.070 (0.277‐4.127) 0.922
Tumor size
<5 vs ≥5 1.835 (0.911‐3.695) 0.089 2.017 (0.794‐5.124) 0.140
T A B L E  3  Univariate and multivariate 
Cox proportional hazards model showing 
variables that affect overall survival in 
ESCC patients (n = 80)
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P‐value HR (95% CI) P‐value
Age
≤60 vs >60 1.710 (0.806‐3.629) 0.162 2.018 (0.883‐4.611) 0.096
Gender
Male vs Female 5.266 (1.221‐22.713) 0.026 7.807 (0.973‐62.650) 0.053
Differentiation
Poor‐Moderate vs Well 1.168 (0.534‐2.555) 0.698 0.896 (0.336‐2.390) 0.826
pT status
T3‐T4 vs T1‐T2 1.279 (0.615‐2.662) 0.510 1.274 (0.406‐3.999) 0.678
pN status
N1‐N3 vs N0 2.015 (0.975‐4.164) 0.058 1.132 (0.343‐3.730) 0.839
Distant metastasis
M1 vs M0 2.177 (0.649‐7.298) 0.208 2.399 (0.572‐10.059) 0.232
pTNM stage
III‐IV vs I‐II 2.391 (1.161‐4.922) 0.018 2.337 (0.591‐9.239) 0.226
Alcohol use
Yes vs No 2.008 (0.698‐5.780) 0.196 2.357 (0.769‐7.223) 0.134
NCOA1 expression
High vs Low 1.601 (0.692‐3.705) 0.272 2.936 (1.140‐7.563) 0.026
T A B L E  4  Univariate and multivariate 
Cox proportional hazards model showing 
variables that affect overall survival in 
ESCC patients from TCGA dataset (n = 95)
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cohort (Table 3) and the TCGA dataset (Table 4) showed that 
NCOA1 expression is an independent predictor of prognosis 
for ESCC patients with a hazard ratio (HR) of 2.386 (95% 
confidence interval [CI] = 1.049‐5.426, P = 0.038) and 2.936 
(CI = 1.140‐7.536, P = 0.026), respectively. These data indi-
cate that the levels of NCOA1 in human ESCC are closely 
associated with patient outcome.
3.3 | The effect of NCOA1 on growth, 
migration, and invasion of ESCC Cells
To dissect the underlying molecular mechanisms of el-
evated levels of NCOA1‐mediated cellular behaviors, we 
knocked down NCOA1 by shRNA technique and ana-
lyzed the effect on cell proliferation, migration, and inva-
sion. Since KYSE510 has the highest NCOA1 expression 
among all the ESCC cells analyzed (Figure 1C), we de-
cided to conduct these experiments in this specific cell 
line. First, we estimated the knockdown efficiencies of two 
shRNAs (shNCOA1 #1 and shNCOA1 #2) and found that 
both shRNAs knocked down NCOA1 efficiently although 
shRNA2 appears to be a bit better than shRNA1 (Figure 
S2). We then transfected KYSE510 cells with shRNA2 
and conducted different assays using the xCELLigence 
system. Figure 4A showed that compared to the control 
knocking down NCOA1 significantly inhibited prolifera-
tion of KYSE510 cells (P < 0.05). In addition, Figure 4B,C 
showed that knockdown NCOA1 in KYSE510 cell signifi-
cantly decreased cell migration and invasion (P < 0.05). 
These data altogether indicate that NCOA1 plays essential 
roles in ESCC cell growth, migration, and invasion. These 
observations are in line with the fact that elevated levels 
of NCOA1 in ESCC were accompanied by aggressive pro-
gression and poor patient outcomes.
3.4 | The oncogenic role of NCOA1 in ESCC 
through multiple signaling pathways
Since NCOA1 has been reported to be involved in multiple 
signaling pathways in a wide spectrum of cancer types, we 
F I G U R E  4  NCOA1 in ESCC cell 
metastasis. A, In vitro xCELLigence 
growth assay of KYSE510 cells transfected 
with shNCOA1 #2 or shCtrl (Left panel) 
and cell index values at the end of the 
experiments (Right panel). The migration 
(B) and invasion (C) of KYSE510 cells 
transfected with shNCOA1 #2 or shCtrl 
were determined using the xCELLigence 
system and cell index values at the end 
of the experiments (Right panel). The 
cell index values represent the relative 
change measured by electrical impedance. 
Representative data from three independent 
experiments are shown in (A, B, and 
C). Data are means ± SD, *P < 0.05, 
**P < 0.01 by Student's t test
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decided to conduct a gene set enrichment analysis (GSEA) of 
the published human ESCC expression profile (GSE23400). 
The results from this analysis suggest that in ESCC cells both 
VEGF and MEK pathways are robustly positively correlated 
with NCOA1 (Figure 5). Whether the effect of NCOA1 on 
ESCC cell growth, migration, and invasion are through ei-
ther or both VEGF and MEK pathways need to be further 
investigated.
4 |  DISCUSSION
Despite the fact that dysregulation of NCOA1 has been docu-
mented in multiple types of human cancers,2,27,47-50 the clini-
cal importance of NCOA1 in tumor progression and clinical 
outcome of human ESCC were unappreciated. By analyzing 
multiple ESCC patient cohorts, we defined the heretofore 
undocumented associations between NCOA1, malignant 
properties, and poor survival of human ESCC and identified 
NCOA1 overexpression as an independent predictive factor 
for ESCC patient prognosis. In addition, we have shown that 
NCOA1 plays essential roles in growth, migration, and inva-
sion of ESCC cells. These findings underscore the rationale 
for using NCOA1 as a biomarker and potential molecular tar-
get for potential treatment.
NCOA1 overexpression has been demonstrated in mul-
tiple cancers.47,51-55 The elevated levels of NCOA1 mRNA 
and increased gene copy number of NCOA1 found in this 
research suggest that both gene amplification and increased 
transcription could be part of the underlying mechanisms of 
NCOA1 overexpression in human ESCC. In addition, Cox 
analysis showed that the protein levels of NCOA1 are in-
versely proportional to ESCC patient survival. This suggests 
that NCOA1 could also serve as a potential biomarker for 
ESCC prognosis. All these findings are consistent with the 
report that patients with NCOA1 overexpression along with 
low expression of miR‐105‐1 were closely associated with 
both poor overall survival and progression‐free survival in 
hepatocellular cancer.56
Although NCOA1 is the founding member of the p160 
family, its functional roles in oncogenesis and progression 
are not as well‐established as that of SRC‐3, another mem-
ber of the family with well‐defined oncogenic activity. It has 
been reported that NCOA1 can promote proliferation of both 
breast cancer26 and hepatocellular cancer cells.56 But results 
from mice with NCOA1 deletion suggest that NCOA1 is ca-
pable of promoting breast cancer metastasis without affect-
ing primary tumor growth, and mechanistically proposed as 
through NCOA1 mediated crosstalk between tumor cells and 
their microenvironment.16 We demonstrated that NCOA1 
plays essential roles in ESCC cell growth, migration, and me-
tastasis suggesting that NCOA1 is important in each of these 
processes in ESCC cells. These ambiguous results suggest 
that NCOA1’s diverse and distinct functions are likely can-
cer‐type specific.
F I G U R E  5  NCOA1 expression is positively correlated with both the VEGF and MEK pathways in ESCC. NCOA1 is positively associated 
with oncogenic pathways. Gene set enrichment analyses showed positive correlations between NCOA1 expression and a VEGF gene signature 
(VEGF_A_UP.V1_UP_137) and a MEK gene signature (MEK_UP.V1_UP_194) in a published cohort of ESCC patients (GSE23400)
5214 |   Wang et al.
Given the marked gender disparity in incidence and clin-
ical outcomes of human ESCC, one intriguing question is 
how sex steroid signaling pathways are involved in the reg-
ulation of ESCC oncogenesis and progression.42,57 We and 
others have previously shown that AR and ERβ signaling 
pathways play important roles in tumorigenesis and progres-
sion of esophageal carcinoma. Coactivators such as NCOA1 
are considered as master modulators in the coordination of 
nuclear receptor transcription and subsequent sex steroid‐me-
diated signaling pathways. Based on the fact that NCOA1 is 
overexpressed in both patient samples and ESCC cancer cell 
lines, further study to better understand the interplay between 
NCOA1 and sex steroid receptors (ie, AR and ER) in ESCC 
is warranted.
In summary, we found that NCOA1 overexpression is a 
common phenomenon in both ESCC patients and ESCC cell 
lines. Overexpressed NCOA1 plays essential roles in each of 
the ESCC progression processes including proliferation, mi-
gration, and invasion. Therefore, the levels of NCOA1 could 
be used as a potential prognostic biomarker and targeting 
NCOA1 could be a strategy in the development of therapies 
for ESCC treatment.
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